Compass Therapeutics (NASDAQ:CMPX) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

CMPX has been the topic of several other research reports. Lifesci Capital started coverage on Compass Therapeutics in a report on Monday, October 6th. They set an “outperform” rating and a $10.00 price objective on the stock. Leerink Partners raised Compass Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 26th. Cantor Fitzgerald started coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They set an “overweight” rating on the stock. Compass Point set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, October 6th. Finally, Citizens Jmp began coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $12.23.

Check Out Our Latest Research Report on Compass Therapeutics

Compass Therapeutics Stock Performance

Shares of CMPX opened at $6.52 on Friday. Compass Therapeutics has a 52-week low of $1.33 and a 52-week high of $6.71. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -14.49 and a beta of 1.46. The business’s fifty day moving average is $5.49 and its 200-day moving average is $4.30.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. As a group, research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. boosted its holdings in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares in the last quarter. Creative Planning acquired a new stake in Compass Therapeutics in the second quarter worth $30,000. Flagship Harbor Advisors LLC bought a new stake in Compass Therapeutics in the fourth quarter valued at $32,000. Strs Ohio bought a new position in shares of Compass Therapeutics during the 1st quarter worth about $34,000. Finally, Apollon Wealth Management LLC acquired a new stake in shares of Compass Therapeutics in the 3rd quarter valued at about $35,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.

Further Reading